Company Description
Bluejay Diagnostics, Inc. operates as a medical diagnostics company.
The company offers the Symphony platform, a technology platform comprising the Symphony analyzer that orchestrates whole blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and the Symphony Cartridge, which includes reagents and components.
It also provides the ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis.
In addition, the company develops Symphony IL-6 tests for the monitoring of disease progression in critical care settings.
Further, it is developing additional tests for Symphony, such as tests for myocardial infraction and congestive heart failure.
Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.
| Country | United States |
| Founded | 2015 |
| IPO Date | Nov 10, 2021 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Indranil Dey |
Contact Details
Address: 360 Massachusetts Avenue, Suite 203 Acton, Massachusetts 01720 United States | |
| Phone | 844 327 7078 |
| Website | bluejaydx.com |
Stock Details
| Ticker Symbol | BJDX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $10.00 |
| CIK Code | 0001704287 |
| CUSIP Number | 095633103 |
| ISIN Number | US0956333019 |
| Employer ID | 47-3552922 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Indranil Dey | Principal Financial, Accounting and Executive Officer, President, Chief Executive Officer and Director |
| Kevin Vance | Chief Commercial Officer |
| Mark W. Feinberg M.D., Ph.D. | Chief Medical Advisor |
| Dr. Mark W. Feinberg M.D. | Chief Medical Advisor |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 28, 2025 | 8-K | Current Report |
| Jun 20, 2025 | 8-K | Current Report |
| Jun 4, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jun 4, 2025 | 8-K | Current Report |
| May 28, 2025 | 8-K | Current Report |
| May 16, 2025 | DEF 14A | Other definitive proxy statements |
| May 13, 2025 | 10-Q | Quarterly Report |
| May 8, 2025 | 424B3 | Prospectus |
| May 7, 2025 | EFFECT | Notice of Effectiveness |
| May 6, 2025 | PRE 14A | Other preliminary proxy statements |